Visallergol eye drops 0.2%, 2.5ml

Composition

>1 ml contains:

• Active ingredient-olopatadine hydrochloride 2.22 mg (equivalent to olopatadine 2 mg),

excipients:

• benzalkonium chloride,
• povidone K-29/32,
• sodium hydrophosphate anhydrous,
• sodium chloride,
• disodium edetate,
• sodium hydroxide,
• hydrochloric acid,
• water for injection.

Pharmacological action

Pharmacokinetics When applied topically, systemic absorption is low. Cmax of olopatadine in blood plasma is reached within 2 hours and ranges from 0.5 ng / ml to 1.3 ng / ml. T1 / 2 in plasma is 3 hours. It is excreted mainly by the kidneys,60-70% – unchanged. Pharmacodynamicolopatadine has an anti-allergic effect, is a selective inhibitor of histamine H1-receptors, and also inhibits the release of inflammatory mediators from mast cells. It has no effect on alpha-adrenergic, dopamine, muscarinic type 1 and 2, as well as serotonin receptors.

Indications

To prevent itching in the eyes associated with allergic conjunctivitis.

Use during pregnancy and lactation

There is no sufficient experience in using the drug during pregnancy and lactation. The use of the drug during pregnancy is possible if the expected therapeutic effect exceeds the potential risk to the fetus. Visallergol should not be used during breastfeeding. If it is necessary to use the drug, breastfeeding should be discontinued.

Contraindications

-Hypersensitivity to the components of the drug-children under 8 years of age

Side effects

In 10% of cases the symptoms are similar to the symptoms of colds and pharyngitis some cases (less than 5%)- blurred vision, burning or stinging, conjunctivitis, dry eyes, foreign body sensation, hyperemia, hypersensitivity, keratitis, eyelid edema, pain and subrosia – asthenia, back pain, flu-like syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion.

Interaction

Studies of the interaction of olopatadine with other drugs have not been conducted. In vitro studies have shown that olopatadine does not inhibit the metabolic reactions associated with cytochrome P-450 isoenzymes 1A2,2C8,2C9,2C19,2D6,2E1AND 3A4. These results indicate a low probability that olopatadine will enter into metabolic reactions when co-administered with other active substances. If necessary, it can be used in combination with other topical ophthalmic medications. In this case, the interval between their use should be at least 5 minutes.

How to take, course of use and dosage

For topical application in the eyes. The drug is not intended for injection or oral use. The drug Visallergol is instilled 1 drop into the lower conjunctival sac of the affected eye (s) 1 time a day. The duration of treatment is determined by the doctor. When instilling the solution, do not touch the tip of the pipette to the eyes or any other surface to avoid contamination of the solution. It is necessary to close the lid tightly after using the drug.

Overdose

Symptoms: if applied topically, overdose is unlikely. Treatment: if an excessive amount of the drug gets into the eyes, it is recommended to rinse the eyes with plenty of warm water.

Special instructions

Olopatadine hydrochloride is a topical anti-allergic / antihistamine, with low systemic absorption when applied topically. If any adverse events or signs of hypersensitivity occur, the drug should be discontinued. Olopatadine hydrochloride 0.2% should not be used to relieve redness of the eyes caused by wearing contact lenses. In this case, the patient should stop wearing contact lenses. The benzalkonium chloride contained in the preparation can be absorbed by contact lenses. Before instillation of the drug, the lenses should be removed and replaced no earlier than 20 minutes after instillation of the drug. Benzalkonium chloride, which is widely used as a preservative in ophthalmic products, has been shown to cause spot keratopathy and / or toxic ulcerative keratopathy according to a number of studies. Since the drug contains benzalkonium chloride, it is necessary to carefully monitor the eye condition of patients with dry eye syndrome with frequent or prolonged use, as well as in patients with damaged cornea. Dose adjustment of the drug in patients with kidney and liver pathologies, as well as in the elderly, is not required. Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanismsmine it is recommended to drive a car and engage in other activities that require increased concentration of attention and speed of psychomotor reaction immediately after instillation (blurred visual perception may develop). In this case, it is necessary to wait for some time before restoring vision.

Form of production

Eye drops

Storage conditions

Store at a temperature of 2°C to 25 °C. Do not freeze it. Keep out of reach of children!

Shelf

life is 2 years. The application period after opening the bottle is 28 days. Do not use after the expiration date.

Active ingredient

Olopatadine

Conditions of release from pharmacies

By prescription

Dosage form

eye drops

Description

Children as prescribed by a doctor, Adults as prescribed by a doctor, Nursing mothers as prescribed by a doctor, Pregnant women as prescribed by a doctor, Children over 3 years of age

Indications

Allergic Conjunctivitis, Allergy